NCT04479267View on ClinicalTrials.gov

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 21, 2020

Primary Completion Date

June 19, 2025

Study Completion Date

July 19, 2026

Conditions
Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 RearrangementsDouble Expressor LymphomaHigh-grade B-cell Lymphoma
Interventions
DRUG

Prednisone

Given PO

DRUG

Prednisolone

Given IV

DRUG

Methylprednisolone

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Polatuzumab Vedotin

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

Trial Locations (1)

48201

Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER